FEASIBILITY OF RADIOIODINE DOSIMETRY USING A SMALL FIELD OF VIEW GAMMACAMERA; PILOT STUDY

English version České info

Nowadays, it is crucial to deal with the dosimetry issues in the light of 2013/59 EURATOM recommendation, where it is clearly defined that dosimetry will be required even for the targeted radionuclide therapy (TRT). The aim of this pilot study was to investigate and to verify the possibilities of dosimetry for patients undergoing first Radioiodine therapy (RAIT) using a small single head mobile gamma camera.

Camera Solo mobile was used for quantitative imaging of ¹³¹I accumulation in remnants of patients' thyroids and ¹³¹I accumulating nodes (neck region). Vials with a known activity of ¹³¹I were used to calibrate the system. The patient-volunteers were around 3 months after thyreoablation due to thyroid carcinoma. The weight of the accumulating remnants or nodes was established using ultrasound or roughly estimated using phantom measurements.

The absorbed doses within remnants or nodes vary from 40 Gy up to 780 Gy with an uncertainty from 25% up to 100% depending mainly on the mass of the remnants estimation. A consequent follow-up is being done. The dose assessment could be done using cheaper small single-head gammacamera what would safe time of the standard ones. Uncertainty is supposed to be significantly reduced by further processes optimization.

Keywords:
Radioiodine, therapy, dosimetry, quantitative imaging

Autoři: Pavel Solný ^1,2; Petr Vlček ²; Lenka Jonášová ²; Jaroslav Zimák ²
Působiště autorů: Department of Dosimetry and Application of Ionizing Radiation Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Czech Republic (DDAIR) ¹; Department of Nuclear Medicine and Endocrinology 2nd Faculty of Medicine, Charles University in Prague and Motol University, Prague, Czech Republic (DNME) ²
Vyšlo v časopise: Lékař a technika - Clinician and Technology No. 3, 2015, 45, 82-87
Kategorie: Původní práce

Souhrn

Keywords:
Radioiodine, therapy, dosimetry, quantitative imaging

Zdroje

[1] Maxon, H. R., Englaro, E. E., Thomas, S. R., Hertzberg, V. S., Hinnefeld, J. D., Chen, L. S., Aden, M. D. (1992). Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 33(6), 1132–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1597728

[2] Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1941–59. doi:10.1007/s00259-008-0883-1.

[3] Lassmann, M., Hänscheid, H., Chiesa, C., Hindorf, C., & Flux, G. (2008). EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I : blood and bone marrow dosimetry in differentiated thyroid cancer therapy, 1405–1412. doi: 10.1007/s00259-008-0761-x.

[4] Flux, G. D., Haq M., Chittenden, S. J., et al. (2009). A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 37; 270–275.

[5] Lassmann, M., Chiesa, C., Flux, G., & Bardiès, M. (2010). EANM Dosimetry Committee guidance document : good practice of clinical dosimetry reporting. doi: 10.1007/s00259-010-1549-3.

[6] Hänscheid, H., Canzi, C., Eschner, W., Flux, G., Luster, M., Strigari, L., & Lassmann, M. (2013). EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. European Journal of Nuclear Medicine and Molecular Imaging, 40(7), 1126–34. doi: 10.1007/s00259-013-2387-x.

[7] Bardiès, M., Flux, G., Lassmann, M., Monsieurs, M., Savolainen, S., & Strand, S.-E. (2006). Quantitative imaging for clinical dosimetry. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 569(2), 467–471. doi:10.1016/j.nima.2006.08.068.

[8] Flux, G. D., Guy, M. J., Beddows, R., Pryor, M., & Flower, M. a. (2002). Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Physics in Medicine and Biology, 47(17), 3211–23. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12361219.

[9] Hackshaw A, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007; 92(1):28–38.

[10] Nikzad, S. (2011). Determination of organ doses in radioiodine therapy using medical internal radiation dosimetry (MIRD) method, 8(4), 249–252.

[11] Gholamrezanezhad A, 12 Chapters on nuclear medicine, Chapt. 2 Internal radiation models and applications; Amato E. et al. InTech, Janeza Trdine 9, 51000 Rijeka, Croatia; ISBN 978-953-307-802-1, 26–50.

[12] Snyder, W. et al. (1975). “S” absorbed dose per unit cumulated activity for selected radionuclides and organs MIRD Pamphlet No. 11. New York (NY): Society of Nuclear Medicine.

[13] Eschmann, S. M., Reischl, G., Bilger, K., Kupferschläger, J., Thelen, M. H., Dohmen, B. M., … Bares, R. (2002). Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. European Journal of Nuclear Medicine and Molecular Imaging, 29(6), 760–7. doi: 10.1007/s00259-002-0775-8.

[14] Sgouros, G., Kolbert, K. S., Sheikh, A., Pentlow, K. S., Mun, E. F., Barth, A., … Larson, S. M. (2004). Patient-Specific Dosimetry for 131 I Thyroid Cancer Therapy Using 124 I PET and.

Lassmann, M., Reiners, C., & Luster, M. (2010). Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocrine-Related Cancer, 17(3), R161–72. doi: 10.1677/ERC-10-0071.

[15] Dorn, R., Kopp, J., Vogt, H., Heidenreich, P., Carroll, R. G., & Gulec, S. a. (2003). Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 44(3), 451–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12621014

[16] Furhang, E. E., Larson, S. M., Buranapong, P., & Humm, J. L. (1999). Thyroid cancer dosimetry using clearance fitting. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 40(1), 131–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9935068

[17] IAEA-TECDOC-1608. (2009), (March).

[18] Sisson, J. C. (2002). Practical Dosimetry of Carcinoma 131 I in Patients with Thyroid, 17(1), 101–106.